127 related articles for article (PubMed ID: 1676715)
21. [Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Rakov AL; Makarov IuS; Gorbakov VV; Mironenko DA; Golochalova TV
Voen Med Zh; 2001 Sep; 322(9):54-8. PubMed ID: 11668793
[No Abstract] [Full Text] [Related]
22. Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.
Wilder-Smith CH; Halter F; Merki HS
Dig Dis Sci; 1991 Dec; 36(12):1685-90. PubMed ID: 1748035
[TBL] [Abstract][Full Text] [Related]
23. Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton MI; Sercombe J; Pounder RE
Aliment Pharmacol Ther; 2001 Oct; 15(10):1579-83. PubMed ID: 11563997
[TBL] [Abstract][Full Text] [Related]
24. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
Thomson AB
Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583
[TBL] [Abstract][Full Text] [Related]
25. Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
Bianchi Porro G; Dicenta C; Cook T; Humphries TJ
J Clin Gastroenterol; 1987; 9 Suppl 2():14-8. PubMed ID: 2887613
[TBL] [Abstract][Full Text] [Related]
26. Comparison of ranitidine 300 mg twice daily, 300 mg at night and placebo on 24-hour intragastric acidity of duodenal ulcer patients.
Merki HS; Witzel L; Walt RP; Neumann J; Scheurle E; Kaufmann D; Mappes A; Heim J; Röhmel J
Aliment Pharmacol Ther; 1987 Jun; 1(3):217-23. PubMed ID: 2979224
[TBL] [Abstract][Full Text] [Related]
27. Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
Yasutake K; Amano M; Mizokami Y; Kubota S; Fukumoto H; Imamura Y; Yokoya H; Irie K
J Int Med Res; 1998; 26(1):25-36. PubMed ID: 9513074
[TBL] [Abstract][Full Text] [Related]
28. Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
Savarino V; Mela GS; Zentilin P; Cutela P; Mele R; Celle G
J Clin Pharmacol; 1993 Jan; 33(1):70-4. PubMed ID: 8429117
[TBL] [Abstract][Full Text] [Related]
29. Single morning and nightly doses of ranitidine 300 mg: an appraisal of their antisecretory effects by continuous pH monitoring.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Cutela P; Celle G
Digestion; 1991; 48(3):141-8. PubMed ID: 1916034
[TBL] [Abstract][Full Text] [Related]
30. Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.
Akhtar MA; Rashid P; Khan MA
J Pak Med Assoc; 1990 Jun; 40(6):136-7. PubMed ID: 1975277
[TBL] [Abstract][Full Text] [Related]
31. The effects of fasting on 24-h gastric secretion of patients with duodenal ulcers resistant to ranitidine.
Johnston DA; Wormsley KG
Aliment Pharmacol Ther; 1989 Oct; 3(5):471-9. PubMed ID: 2518860
[TBL] [Abstract][Full Text] [Related]
32. Action of famotidine and ranitidine on prostaglandin E2 (PGE2) content of fundic and duodenal mucosa in duodenal ulcer patients.
Lezoche E; Vagni V; D'Alessandro MD; Mariani P; Carlei F; Lomanto D; Nardovino M; Martelli A; Speranza V
Drugs Exp Clin Res; 1987; 13(10):655-8. PubMed ID: 2892658
[TBL] [Abstract][Full Text] [Related]
33. [In vivo evaluation of the effect of antacids and H2 receptor blockaders on the intragastric pH in gastric and duodenal ulcer].
Waserstein M; Dacoll C; Cohen H; Gamboa L; Brener A; de Mizrahi JB; Sempol D; Neumark A; Nieto F; Tenzer S
Acta Gastroenterol Latinoam; 1985; 15(4):243-55. PubMed ID: 2878555
[TBL] [Abstract][Full Text] [Related]
34. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Savarino V; Mela GS; Scalabrini P; Sumberaz A; Fera G; Zentilin P; Celle G
Am J Gastroenterol; 1988 Sep; 83(9):917-22. PubMed ID: 2901220
[TBL] [Abstract][Full Text] [Related]
35. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Khasawneh SM; Affarah HB
Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
[TBL] [Abstract][Full Text] [Related]
36. [Famotidine versus ranitidine in the acute treatment of duodenal ulcer. A multicenter comparative study in Germany].
Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
Z Gastroenterol; 1985 Feb; 23(2):47-51. PubMed ID: 2865859
[TBL] [Abstract][Full Text] [Related]
37. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
38. [Acid-related pathology and prolonged continuous gastric pH monitoring. Physiopathologic findings and therapeutic implications].
Celle G; Savarino V; Mela GS
Recenti Prog Med; 1989 Sep; 80(9):485-92. PubMed ID: 2574489
[TBL] [Abstract][Full Text] [Related]
39. Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine.
Rohner HG; Gugler R
Am J Med; 1986 Oct; 81(4B):13-6. PubMed ID: 2877569
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.
Savarino V; Scalabrini P; Mela GS; di Timoteo E; Percario G; Magnolia MR; Celle G
Dig Dis Sci; 1988 Mar; 33(3):293-7. PubMed ID: 3125025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
